VitaNova Life Sciences Corporation
VNOV
$4.83
-$2.67-35.60%
OTC PK
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 66.14% | 311.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 66.14% | 311.07% | |||
| Cost of Revenue | 136.50% | 373.79% | |||
| Gross Profit | 21.28% | 279.07% | |||
| SG&A Expenses | 66.83% | 59.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 102.17% | 140.57% | |||
| Operating Income | -52.92% | 406.17% | |||
| Income Before Tax | -52.97% | 406.48% | |||
| Income Tax Expenses | 43.46% | 356.83% | |||
| Earnings from Continuing Operations | -224.02% | 177.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -224.02% | 177.32% | |||
| EBIT | -52.92% | 406.17% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -223.26% | 176.79% | |||
| Normalized Basic EPS | -52.70% | 408.33% | |||
| EPS Diluted | -223.26% | 176.79% | |||
| Normalized Diluted EPS | -52.70% | 408.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||